CLINICAL & PIPELINE·Drug Approval
GSK's Jideytro FDA Approval Bolsters Oncology Portfolio After $10.6B Nuvalent Acquisition
GSK secured FDA approval for Jideytro (zidesamtinib) for ROS1-positive metastatic NSCLC, a key return on its $10.6 billion Nuvalent acquisition. This approval accelerates GSK's oncology expansion, positioning Jideytro as a next-generation therapy in a competitive but underserved market, with significant implications for procurement and market access strategies.
90-Day Activity